From Tuberculosis › Chapter 2: Clinical presentation · Médecins Sans Frontières, Current online edition, 2026
Clinical presentation, symptoms and differential diagnosis of pulmonary tuberculosis for clinicians and public health professionals.
- Issuer
- Médecins Sans Frontières
- Edition
- Current online edition, 2026
- Audience
- Clinicians and public health professionals
- Evidence
- Expert consensus
- Reviewed
- 21 Oct 2026 · GMJ
What this guideline says
GMJ summary
This MSF clinical guideline section describes the clinical presentation of pulmonary tuberculosis (PTB), emphasising that prolonged cough lasting more than 2 weeks, with or without sputum production, is the cardinal symptom. Other frequent but less specific features include weight loss, anorexia, fatigue, haemoptysis, shortness of breath, chest pain, moderate fever and night sweats. The guideline stresses that signs and symptoms vary between individuals and typically evolve in a chronic, insidious manner, making thorough history-taking essential.
Advanced forms and complications are common, including respiratory insufficiency from extensive lung destruction, massive haemoptysis from cavitary disease with vessel erosion, and pneumothorax from cavity rupture into the pleural space. In endemic areas, PTB should be considered in any person with respiratory symptoms lasting more than 2 weeks.
The guideline provides a comprehensive differential diagnosis table for non-HIV infected persons, covering bacterial pneumonia, pulmonary abscess, bronchiectasis, lung cancer, and geographically specific conditions such as paragonimiasis and pulmonary echinococcosis. Clinical features and distinguishing characteristics are provided for each condition to aid diagnostic reasoning.
Key points
For clinicians — doses and thresholds as stated in the guideline
- Prolonged cough lasting more than 2 weeks, with or without sputum production, is a common presenting symptom of pulmonary tuberculosis
- In endemic areas, consider PTB diagnosis in any person presenting with respiratory symptoms lasting more than 2 weeks
- Other frequent signs and symptoms include weight loss, anorexia, fatigue, haemoptysis, shortness of breath, chest pain, moderate fever and night sweats
- Advanced complications include respiratory insufficiency from extensive lesions, massive haemoptysis from large cavities with vessel erosion, and pneumothorax from cavity rupture
- Bacterial pneumonia typically presents more acutely with shorter duration and high fever; response to non-TB antibiotics suggests bacterial pneumonia
- Haemoptysis occurs in 20–50% of lung cancer patients and may be mild in bronchiectasis
- In Southeast Asia, West Africa and Latin America, paragonimiasis should be routinely ruled out in presumed PTB cases
- Thorough history-taking is of utmost importance as signs and symptoms vary between individuals and evolve in a chronic, insidious manner
Differential diagnosis for pulmonary tuberculosis
Table extracted from the guideline
| Diseases | Notes |
|---|---|
| Bacterial pneumonia | Usually more acute and shorter in duration; high fever often present. Response to antibiotics with no anti-TB activity suggests bacterial pneumonia. Lobar consolidation is typical of bacterial pneumonia; however, radiography alone cannot differentiate PTB from bacterial pneumonia. |
| Pulmonary abscess | May arise from aspiration in individuals with impaired consciousness (coma, intoxication with alcohol/drugs, etc.). Foul-smelling, purulent sputum. Cavities typically have a thick wall and air fluid levels. |
| Bronchiectasis | Frequent complication of successive, poorly-treated bronchopulmonary infections. Characterised by chronic or repeated episodes of productive cough. Haemoptysis, usually mild, can be present. |
| Lung cancer | History of smoking or environmental exposure (working in a mine, etc.). Haemoptysis in 20 to 50% of patients. |
| Paragonimiasis (lung flukes) | In certain areas of Southeast Asia, West Africa and Latin America. To be routinely ruled out in presumed PTB cases. |
| Pulmonary echinococcosis (hydatid disease) | In Latin America, the Middle East, some Sub-Saharan African countries and China. Lung involvement may cause chronic cough, with or without haemoptysis. Cysts can mimic TB cavities. |
| Pneumocystosis (PCP/PJP) | Common in patients receiving long-term, even low dose, corticosteroid therapy. |
| Less common diseases | Silicosis, sarcoidosis, melioidosis. Cryptococcosis, aspergillosis, histoplasmosis. |
Source: Médecins Sans Frontières, Pulmonary tuberculosis — MSF Tuberculosis. Reproduced in summary form.
From the guideline
Verbatim
“In endemic areas, the diagnosis of PTB should be considered in any person consulting for respiratory symptoms lasting more than 2 weeks.”
Editor’s perspective
Why this matters for Georgia and the region
Prof. Giorgi Pkhakadze, MD, MPH, PhD
Editor-in-Chief, Georgian Medical Journal · Chair, Public Health Institute of Georgia · WHO consultant, health and migration
As Editor-in-Chief of the Georgian Medical Journal and Chair of the Public Health Institute of Georgia, I recognise the critical importance of this MSF guidance for our region. Georgia continues to face substantial TB burden with among the highest MDR-TB rates in the WHO European Region, and delayed diagnosis in primary care remains a persistent challenge. I would emphasise to Georgian clinicians the 2-week respiratory symptom threshold as a simple, practical screening criterion that should trigger TB diagnostic evaluation in every primary care facility and emergency department across the country. The realistic implementation caveat is that differential diagnosis requires access to chest radiography and microbiological confirmation, which remain unevenly distributed outside Tbilisi and regional centres, necessitating continued investment in decentralised diagnostic capacity as part of our national TB programme.
ORCID 0000-0001-7609-4515 · Perspective written for the GMJ Guidelines Library, 21 Oct 2026
Applicability
Georgia and the South Caucasus
Georgia remains a high-burden TB country in the WHO European Region, with multidrug-resistant TB rates among the highest globally. This MSF guidance on recognising pulmonary TB is directly applicable to Georgian clinicians working in primary care, outpatient departments and emergency settings where delayed diagnosis remains a challenge. The differential diagnosis table is particularly relevant given Georgia’s geographical position: whilst paragonimiasis is not endemic, pulmonary echinococcosis is present in the region and should be considered. National TB programmes in Georgia and neighbouring Armenia and Azerbaijan should ensure that the 2-week respiratory symptom threshold for TB screening is consistently applied across all levels of the health system, and that clinicians are trained to distinguish TB from common mimics such as bacterial pneumonia and bronchiectasis, which are frequently managed in primary care.
Questions this guideline answers
Quick answers
What is the key symptom threshold for considering pulmonary TB in endemic areas?
In endemic areas, pulmonary TB should be considered in any person presenting with respiratory symptoms lasting more than 2 weeks. Prolonged cough (more than 2 weeks), with or without sputum production, is the most common presenting symptom.
How can bacterial pneumonia be distinguished from pulmonary TB?
Bacterial pneumonia is usually more acute and shorter in duration, with high fever often present. Response to antibiotics with no anti-TB activity suggests bacterial pneumonia. However, radiography alone cannot differentiate PTB from bacterial pneumonia, even though lobar consolidation is typical of bacterial pneumonia.
What are the life-threatening complications of advanced pulmonary TB?
Advanced pulmonary TB can cause respiratory insufficiency due to extensive lesions and destroyed lungs, massive haemoptysis due to large cavities with hyper-vascularisation and erosion of vessels, and pneumothorax due to rupture of a cavity into the pleural space.
Which geographically-specific diseases should be considered in the differential diagnosis of pulmonary TB?
Paragonimiasis (lung flukes) should be routinely ruled out in Southeast Asia, West Africa and Latin America. Pulmonary echinococcosis (hydatid disease) should be considered in Latin America, the Middle East, some Sub-Saharan African countries and China, where cysts can mimic TB cavities.
Related on GMJ
Interconnected resources
Dictionary of Public Health
Conditions A–Z
GMJ News coverage
Other guidelines on this topic
- Acute cystitis — MSF Clinical guidelines
- Handbook for Integrated Vector Management in the Americas
- Recommendations for Cleaning and Disinfection in Homes with Suspected or Confirmed Cases of COVID-19
- PAHO Does Not Recommend Taking Products that Contain Chlorine Dioxide, Sodium Chlorite, Sodium Hypochlorite, or Derivatives
- Essential Medicines List for Management of Patients Admitted to Intensive Care Units with Suspected or Confirmed COVID-19 Diagnosis
- Issuer
- Médecins Sans Frontières
- Guideline
- Tuberculosis
- Chapter
- Chapter 2: Clinical presentation
- Type
- Clinical guideline (chapter)
- Edition
- Current online edition, 2026
- Status
- Current
- Published
- 2026-10-14
- Scope
- Clinical presentation of pulmonary tuberculosis
- Audience
- Clinicians and public health professionals
- Evidence
- Expert consensus
- Record history
- Created 21 Oct 2026 · updated 21 Oct 2026 · next check Apr 2027
Médecins Sans Frontières. Pulmonary tuberculosis. In: Tuberculosis [Internet]. Paris: MSF; 2026 [cited 2026 Oct 14]. Available from: https://medicalguidelines.msf.org/en/viewport/TUB/english/2-1-pulmonary-tuberculosis-23791779.htmlGMJ Guidelines Library records are original summaries written by the GMJ editorial team from the issuer’s published document and reviewed by a physician. They do not replace the full guideline. The document is the copyright of its issuer and is linked, not hosted. Spotted an error or a newer edition? Tell the Guidelines Desk.
Was this article helpful?
